The chemical class known as PNAd Inhibitors encompasses a range of compounds that interact with the PNAd protein to modulate its biological function. This class of inhibitors is distinguished by their ability to interfere with the specific enzymatic activity of PNAd or its associated pathways in cellular protein regulation. The primary mode of action for these inhibitors involves altering the N-end rule pathway of protein degradation, a crucial cellular mechanism where PNAd plays a vital role. By targeting this pathway, these inhibitors can modify the stability and turnover of specific proteins within the cell.
In the context of the N-end rule pathway, PNAd functions by recognizing and modifying substrates, which are then earmarked for degradation. Inhibitors in this class can act by directly interfering with the active site of PNAd, thereby preventing it from executing its normal enzymatic function. This interference can be achieved through the binding of inhibitors to the active site, effectively blocking access to natural substrates. Alternatively, these compounds can bind to allosteric sites on the PNAd molecule, inducing conformational changes that reduce the enzyme's activity, thus indirectly affecting its function. Apart from direct interaction with PNAd, inhibitors in this class can also exert their effects by modulating related cellular processes. For instance, some inhibitors can influence the proteasome, the complex responsible for degrading proteins tagged by the N-end rule pathway. By inhibiting the proteasome, these compounds can cause an accumulation of substrates that PNAd typically targets, indirectly impacting its function. Other inhibitors work by altering upstream or downstream elements in the protein degradation pathway. For example, some compounds can affect the activity of proteases or modify cellular states like redox balance, which in turn can influence the overall pathway in which PNAd is involved. Overall, PNAd inhibitors represent a diverse group of compounds that share the common goal of modulating the activity of PNAd, either through direct interaction or by influencing related cellular mechanisms. These inhibitors are characterized by their varied mechanisms of action, each impacting the PNAd protein or its associated pathways in different but significant ways. Their role in altering protein stability and degradation pathways underscores their importance in the study of cellular protein regulation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that could potentially inhibit PNAd by altering the degradation pathway of proteins that PNAd acts upon, leading to a change in PNAd's functional dynamics. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin could potentially inhibit PNAd by disrupting the proteasomal degradation process, which is downstream of the N-end rule pathway where PNAd functions. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a specific proteasome inhibitor, could potentially inhibit PNAd by modifying the proteasomal degradation of PNAd substrates, thus affecting the overall N-end rule pathway. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin could potentially inhibit PNAd by altering protease activity in pathways that are related to PNAd's functional sphere in protein degradation. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E64, a cysteine protease inhibitor, could potentially inhibit PNAd by impacting the broader protein degradation pathways, thus indirectly affecting PNAd's function. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin, as a proteasome inhibitor, could potentially inhibit PNAd by affecting the degradation of proteins that are substrates of the N-end rule pathway. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK, a pan-caspase inhibitor, could potentially inhibit PNAd by modifying apoptosis pathways, which could in turn influence PNAd's role in protein stability. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $153.00 $214.00 $4000.00 | 39 | |
Auranofin could potentially inhibit PNAd by affecting cellular redox states, which might influence PNAd's activity or substrate stability. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A, with its proteasome-inhibiting properties, could potentially inhibit PNAd by modifying its role in the N-end rule pathway. | ||||||
1,10-Phenanthroline | 66-71-7 | sc-255888 sc-255888A | 2.5 g 5 g | $23.00 $32.00 | ||
O-Phenanthroline, a metalloprotease inhibitor, could potentially inhibit PNAd by affecting metal-dependent enzymes, possibly impacting related cellular pathways. | ||||||